Skip to main content

Genetic heritage

Genetic heritage from the Stone Age protects against today's chronic inflammatory bowel diseases


In Europe alone, approximately 2 million people live with chronic inflammatory bowel diseases (IBD), and their incidence has been rising steadily in recent decades. However, a small proportion of the European population carries a genetic variant that provides natural protection against IBD.

A newly published study in the journal eBioMedicine explores how this protective variant can be leveraged to develop modern therapies, demonstrating the potential of evolutionary medicine in addressing chronic diseases of the modern era.

The study, led by the Institute of Clinical Molecular Biology (IKMB) at Kiel University, brought together researchers from genetics, medicine, and archaeology.

"We have demonstrated that this gene variant, which offers protection against inflammatory bowel diseases, was prevalent among the first sedentary farmers in Anatolia and was introduced to Europe through ancient migration movements," explains Prof. Dr. Ben Krause-Kyora from the IKMB, lead author of the study.

The study, part of the ROOTS and "Precision Medicine for Chronic Inflammatory Diseases" (PMI) Clusters of Excellence, analyzed genetic data from 251 human genomes spanning the past 14,000 years across Europe and Anatolia. The researchers focused specifically on the IL23R gene, which plays a key role in immune regulation.

"The exact causes of chronic inflammatory bowel diseases remain unknown. However, previous research has shown that strong immune responses regulated by IL23R are closely linked to these conditions. A reduced function of this pathway appears to provide protection against chronic inflammation," explains Professor Krause-Kyora.


The IL23R variant examined in the study moderates the immune response, preventing excessive inflammation without compromising overall immune function. As a result, individuals carrying this gene variant remain largely protected from infections.

"It's a win-win situation for the body," says co-author Prof. Dr. Dr. Stefan Schreiber, spokesperson for PMI and clinical partner of the research team as a gastroenterologist at the University Medical Center Schleswig-Holstein.

About 10,000–12,000 years ago, approximately 18% of individuals in Anatolian farming communities carried this gene variant. The shift from a Paleolithic lifestyle of hunting and gathering to Neolithic farming likely triggered more frequent inflammatory reactions in individuals.

The researchers hypothesize that the IL23R variant provided protection against this heightened inflammatory status, enhancing survival among the first Neolithic farmers. This could explain its high prevalence in early agrarian societies.

From the Neolithic period onward, migratory movements gradually spread the IL23R variant across Europe over the past 8,000 years. Subsequent population admixture led to its highest prevalence in Southwestern Europe and lowest in Northeastern Europe. Interestingly, this distribution mirrors the regional prevalence of IBD, which is most common in Northern and Eastern Europe. Today, approximately 5% of the European population still carries the variant.

The study sheds light on the history of a gene variant that remains medically significant today. "We now understand why a reduced function of IL23R provides protection against inflammatory conditions. The mechanism by which this variant prevents chronic inflammatory bowel diseases has recently been applied in the development of IBD medications.

"These treatments are considered highly effective with minimal side effects. This example illustrates how we can draw inspiration from nature to develop new therapies," says Schreiber.

genetic heritage, DNA ancestry, inherited traits, genetic lineage, genealogical DNA, ancestral origins, hereditary diseases, genetic diversity, evolutionary genetics, gene expression, family genetics, mitochondrial DNA, Y-chromosome lineage, population genetics, epigenetics, genomic inheritance, biological ancestry, autosomal DNA, genetic markers, personalized genomics

#GeneticHeritage #DNAAncestry #InheritedTraits #GeneticLineage #Genealogy #AncestralOrigins #HereditaryDiseases #GeneticDiversity #EvolutionaryGenetics #GeneExpression #FamilyGenetics #MitochondrialDNA #YChromosome #PopulationGenetics #Epigenetics #GenomicInheritance #BiologicalAncestry #AutosomalDNA #GeneticMarkers #PersonalizedGenomics

International Conference on Genetics and Genomics of Diseases 




For Enquiries: genetics@healthcarek.com 

Get Connected Here 
--------------------------------- 
--------------------------------- 

Comments

Post a Comment

Popular posts from this blog

Fruitful innovation

Fruitful innovation: Transforming watermelon genetics with advanced base editors The development of new adenine base editors (ABE) and adenine-to-thymine/ guanine base editors (AKBE) is transforming watermelon genetic engineering. These innovative tools enable precise A:T-to-G and A:T-to-T base substitutions, allowing for targeted genetic modifications. The research highlights the efficiency of these editors in generating specific mutations, such as a flowerless phenotype in ClFT (Y84H) mutant plants. This advancement not only enhances the understanding of gene function but also significantly improves molecular breeding, paving the way for more efficient watermelon crop improvement. Traditional breeding methods for watermelon often face challenges in achieving desired genetic traits efficiently and accurately. While CRISPR/Cas9 has provided a powerful tool for genome editing, its precision and scope are sometimes limited. These limitations highlight the need for more advanced gene-e...
Post a Comment
Read more

Genetic factors with clinical trial stoppage

Genetic factors associated with reasons for clinical trial stoppage Many drug discovery projects are started but few progress fully through clinical trials to approval. Previous work has shown that human genetics support for the therapeutic hypothesis increases the chance of trial progression. Here, we applied natural language processing to classify the free-text reasons for 28,561 clinical trials that stopped before their endpoints were met. We then evaluated these classes in light of the underlying evidence for the therapeutic hypothesis and target properties. We found that trials are more likely to stop because of a lack of efficacy in the absence of strong genetic evidence from human populations or genetically modified animal models. Furthermore, certain trials are more likely to stop for safety reasons if the drug target gene is highly constrained in human populations and if the gene is broadly expressed across tissues. These results support the growing use of human genetics to ...
Post a Comment
Read more

Genetics study on COVID-19

Large genetic study on severe COVID-19 Bonn researchers confirm three other genes for increased risk in addition to the known TLR7 gene Whether or not a person becomes seriously ill with COVID-19 depends, among other things, on genetic factors. With this in mind, researchers from the University Hospital Bonn (UKB) and the University of Bonn, in cooperation with other research teams from Germany, the Netherlands, Spain and Italy, investigated a particularly large group of affected individuals. They confirmed the central and already known role of the TLR7 gene in severe courses of the disease in men, but were also able to find evidence for a contribution of the gene in women. In addition, they were able to show that genetic changes in three other genes of the innate immune system contribute to severe COVID-19. The results have now been published in the journal " Human Genetics and Genomics Advances ". Even though the number of severe cases following infection with the SARS-CoV-...
Post a Comment
Read more